Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 2/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.31 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14061414 | 0.75 | CA12 (0.56) | CA12CA9PARP1ALOX15HSD17B10 | |
| SCHEMBL1738013 | 0.71 | AHR (0.47) | CA12CA9CYP1A2GAAAHR | |
| SCHEMBL14581370 | 0.70 | CA12 (0.68) | CA12CA9PARP1ALOX15HSD17B10 | |
| SCHEMBL11128890 | 0.69 | PARP1 (0.48) | CA12CA9PARP1ALOX15HSD17B10 | |
| SCHEMBL6630181 | 0.69 | NPC1 (0.48) | PARP1CYP1A2PDPK1PARP10PARP11 | |
| SCHEMBL2948 | 0.69 | — | — | |
| SCHEMBL28776095 | 0.67 | — | — | |
| SCHEMBL517634 | 0.67 | ALOX15 (0.52) | CA12CA9PARP1ALOX15HSD17B10 | |
| SCHEMBL29749158 | 0.67 | ALOX15 (0.52) | CA12CA9PARP1ALOX15HSD17B10 | |
| SCHEMBL517635 | 0.67 | ALOX15 (0.52) | CA12CA9PARP1ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024506-B2 | Compounds | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-02 | — | — | US | disclosed |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-04-30 | — | — | US | disclosed |
| US-11969473-B2 | Multifunctional conjugates | E.P.O.S IASIS RESEARCH AND DEVELOPMENT LIMITED (CY) | 2024-04-30 | — | — | US | disclosed |
| WO-2024073383-A1 | COMPOUNDS FOR THE TREATMENT OF A CENTRAL NERVOUS SYSTEM DISEASE OR DISORDER | PGI DRUG DISCOVERY LLC (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240108629-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) | 2024-04-04 | — | — | US | disclosed |
| WO-2023233148-A1 | CANCER THERAPY | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL, (GB) | 2023-12-07 | — | — | WO | disclosed |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-11-02 | — | — | US | disclosed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| EP-3596061-B1 | COMPOUNDS USEFUL IN THE TREATMENT OR PREVENTION OF A PRMT5-MEDIATED DISORDER | ARGONAUT THERAPEUTICS LTD (GB) | 2023-09-06 | — | — | EP | disclosed |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-8541590-B2 | Proteasome inhibitors and processes for their preparation, purification and use | CEPHALON, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120270840-A1 | Proteasome inhibitors and processes for their preparation, purification and use | CEPHALON INC. (US) | 2012-10-25 | — | — | US | disclosed |
| WO-2012125603-A1 | MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11969473-B2 | Multifunctional conjugates | MKI67, ACP3, CD44 | CA12 484/4885CA9 292/4885PARP1 369/4885 |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | CA12 2894/4885CA9 1403/4885PARP1 707/4885 |
| US-11970469-B2 | Compounds useful in the treatment of disorders associated with mutant RAS | KRAS, NRAS, HRAS | CA12 4335/4885CA9 4357/4885PARP1 4328/4885 |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CDC7, CDK7, CDK17 | CA12 4839/4885CA9 4231/4885PARP1 1174/4885 |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | PWWP2B, WARS1, PNPO | CA12 4883/4885CA9 4876/4885PARP1 2964/4885 |
| US-20120270840-A1 | Proteasome inhibitors and processes for their preparation, purification and use | PSMB1, PSMB11, PSMB7 | CA12 3556/4885CA9 2269/4885PARP1 608/4885 |
| US-11724999-B2 | Inhibitors of RAS-effector protein interactions | KRAS, NRAS, HRAS | CA12 4690/4885CA9 4160/4885PARP1 3580/4885 |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | CA12 2894/4885CA9 1403/4885PARP1 707/4885 |
| US-20240108629-A1 | AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL | AQP3, AQP1, AQP4 | CA12 3686/4885CA9 1945/4885PARP1 4486/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | CA12 4169/4885CA9 4168/4885PARP1 414/4885 |
| US-12024506-B2 | Compounds | KRAS, NRAS, HRAS | CA12 4062/4885CA9 3683/4885PARP1 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.